Introduction: At present, there is a significant amount of data related to biologics used in
pediatric patients with Crohn's disease. This review characterizes the different biological …

The treatment of Crohn's disease in children has undergone a revolution in the past decade
following studies that have demonstrated the efficacy of anti-TNFα agents in producing …

Crohn′ s disease affects increasing numbers of children worldwide. Generally, childhood‐
onset disease runs a more severe course than in adults and has a greater impact on quality …

Introduction: Crohn's disease (CD) is a chronic inflammatory condition that can occur
throughout the gastrointestinal tract. The aims of treatment of children with CD are to induce …

Objective: The antitumor necrosis factor α (TNFα) antibodies infliximab and adalimumab are
effective in inducing and maintaining remission in pediatric patients with Crohn disease …

Paediatric Crohn's disease is associated with a high disease burden and greater
requirement for immunosuppression compared with adult-onset disease. Although anti …

Background We aimed to evaluate the predictors of sustainability of biologic drugs for
paediatric patients with Crohn's disease (CD). Methods The Czech National Prospective …

Purpose There is currently no curative treatment for childhood Crohn's disease (CD). This
meta-analysis aimed to validate the efficacy and safety of adalimumab (ADA) in pediatric …

Antibodies directed to tumour necrosis factor-α (TNF-α) are very effective in treating
paediatric Crohn's disease (CD). Over the last few years, research has provided important …

Aim: To report the cumulative safety profile of biologic therapy with IFX and/or ADA, up to 8
years, in Polish children with moderately to severely active CD. Material and methods: We …